PCM
VTGN icon

Prelude Capital Management’s VistaGen Therapeutics VTGN Stock Holding History

Prelude Capital Management’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-20,200
Closed -$106K – 1372
2023
Q3 		$106K Buy
+20,200
New +$89.7K 0.01% 988
2021
Q1 		– Sell
-5,012
Closed -$292K – 1839
2020
Q4 		$292K Buy
+5,012
New +$128K 0.01% 923

Other funds holding VTGN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Prelude Capital Management's VTGN Position: Q4 2023 in Review

Prelude Capital Management sold out of VistaGen Therapeutics (VTGN) in Q4 2023, closing a stake of 20,200 shares — an estimated $106K sold.

Prelude Capital Management first reported a position in VTGN in Q4 2020 and held it in 2 quarters. The position peaked at $292K in Q4 2020. 46 funds tracked by Wall St. Rank hold VTGN as of Q4 2023.

  • Prelude Capital Management reported no remaining VistaGen Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Prelude Capital Management sold 20,200 VistaGen Therapeutics shares in Q4 2023, an estimated $106K.
  • Prelude Capital Management first reported a position in VistaGen Therapeutics in Q4 2020 and held it in 2 quarters.
  • Prelude Capital Management's VistaGen Therapeutics position peaked at $292K in Q4 2020.
  • 46 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q4 2023.

Based on Prelude Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.